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Abstract
Control of macrophage capacity for apoptotic cell clearance by soluble mediators such as cytokines, prostaglandins and
lipoxins, serum proteins, and glucocorticoids may critically determine the rate at which inflammation resolves. Previous
studies suggested that macrophage capacity for clearance of apoptotic neutrophils was profoundly altered following
binding of CD44 antibodies. We have used a number of different approaches to further define the mechanism by which
CD44 rapidly and specifically augment phagocytosis of apoptotic neutrophils. Use of Fab’ fragments unequivocally
demonstrated a requirement for cross-linking of macrophage surface CD44. The molecular mechanism of CD44-augmented
phagocytosis was shown to be opsonin-independent and to be distinct from the Mer/protein S pathway induced by
glucocorticoids and was not functional for clearance of apoptotic eosinophils. CD44-cross-linking also altered macrophage
migration and induced cytoskeletal re-organisation together with phosphorylation of paxillin and activation of Rac2.
Investigation of signal transduction pathways that might be critical for CD44 augmentation of phagocytosis revealed that
Ca2+ signalling, PI-3 kinase pathways and altered cAMP signalling were not involved, but did implicate a key role for tyrosine
phosphorylation events. Finally, although CD44 antibodies were able to augment phagocytosis of apoptotic neutrophils by
murine peritoneal and bone marrow-derived macrophages, we did not observe a difference in the clearance of neutrophils
following induction of peritonitis with thioglycollate in CD44-deficient animals. Together, these data demonstrate that CD44
cross-linking induces a serum opsonin-independent mechanism of macrophage phagocytosis of apoptotic neutrophils that
is associated with reduced macrophage migration and cytoskeletal reorganisation.
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Introduction
Development of novel, effective therapeutic strategies for treat-
ment of inflammatory diseases requires an understanding the
cellular and molecular mechanisms underlying development and
progression of inflammation [1]. In particular, neutrophil granulo-
cytes are recruited in large numbers in response to infection or tissue
injury and although they represent a vital component of the body’s
response to infectious agents, release of their formidable array of
toxic substances may inflict damage on surrounding tissue and
propagate the inflammatory response [2]. Neutrophil-driven
inflammation and tissue injury is thought to be a key pathological
process in many diseases including rheumatoid arthritis [3],
pulmonary fibrosis [4], the adult respiratory distress syndrome
[5], and inflammatory bowel disease [6] that are characterized by a
failure in the process of resolution of inflammation, resulting in
progression to chronic inflammation and scarring [7].
A critical event in the resolution of inflammatory responses is
the clearance of recruited inflammatory granulocytes, particularly
via the co-ordinated induction of programmed cell death
(apoptosis) and subsequent clearance of apoptotic cells by tissue
phagocytes [8]. This mechanism has been elegantly confirmed in
experimental models of inflammation, where acceleration of
neutrophil apoptosis facilitates early resolution and reduction in
tissue injury [9]. Neutrophil apoptosis results in loss of expression
and function of adhesion molecules [10] and greatly reduced
responsiveness to external stimuli [11], leading to functional
isolation from micro-environmental stimuli. In addition, apoptotic
neutrophils are swiftly recognised and ingested by neighbouring
phagocytes, thereby limiting release of harmful intracellular
contents [12]. Although multiple molecular mechanisms may be
involved in the clearance of apoptotic cells by phagocytes [13],
uptake of apoptotic cells suppresses toll-like receptor-driven
production of pro-inflammatory mediators by macrophages and
can induce release of IL-10 and TGF-b that have the potential to
exert anti-inflammatory effects [14,15].
There is now compelling evidence that defective clearance of
apoptotic cells can profoundly influence development of inflam-
matory disease [16,17] and autoimmunity [18]. Thus, regulation
of macrophage capacity for apoptotic cell clearance by production
and release of soluble mediators such as cytokines [19],
prostaglandins and lipoxins [20,21], serum proteins [22], and
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glucocorticoid hormones [23] may critically determine inflamma-
tory resolution and suppression of autoimmune responses. Our
previous work implicated the multifunctional cell surface receptor
CD44 as a key regulator of macrophage capacity for phagocytosis
of apoptotic cells [24]. The CD44 gene can undergo a complex
pattern of alternative splicing, resulting in the expression of
different protein isoforms that exhibit distinct functional attributes
[25]. CD44 is a receptor for hylauronan [25] and potentially a
number of other ligands including E-selectin [26]. Cell surface
CD44 acts to control assembly of signalling ‘‘platforms’’ that can
regulate cellular behaviour including migration, proliferation and
differentiation [27].
We demonstrated that human macrophage phagocytosis of
apoptotic PMN was rapidly and specifically augmented (,1.5 fold
increase in the percentage of macrophages capable of phagocytosis
of apoptotic PMN and with multiple internalised apoptotic PMN
per macrophage equating to a 4-fold increase in phagocytic index)
following pre-incubation with CD44 monoclonal antibodies.
Although we used microscopy of trypsinised macrophages to
confirm that augmented phagocytosis was specific for apoptotic
PMN, the underlying mechanism was not determined [24]. In this
manuscript, we use a number of different approaches to further
define the mechanism by which CD44 antibodies act to rapidly
and specifically augment phagocytosis of apoptotic neutrophils.
Materials and Methods
Antibodies and other reagents
Reagents were obtained from Sigma-Aldrich (www.sigma-aldrich.
com) unless otherwise stated. Iscove’s DMEM (IDMEM) was from
Invitrogen (www.invitrogen.com). Dextran and PercollTM were from
GE Healthcare (www.gehealthcare.com). Dexamethasone was
obtained from David Bull Laboratories (www.maynepharma.com).
Human Protein S was obtained from Enzyme Research (www.
enzymeresearch.co.uk). Primary monoclonal antibodies (mAb) were
from the following sources: paxillin (IgG1), and anti-phosphotyrosine
(PY20, IgG2b) were from Transduction Laboratories (www.
bdeurope.com). Rat monoclonal recognising mouse granulocytes
(IgG2b, Gr1 - Ly6G) was obtained from R and D systems (www.
rndsystems.com). Goat polyclonal antibody against Rac1 and Rac2
was obtained from Pierce (www.pierce-antibodies.com). MAb
specific for CD44 and variant isoforms were obtained through the
Leukocyte Differentiation Antigen workshop as follows: CD44v3
(clone 3G5, IgG2b), CD44v4 (clone FW11-10-3, IgG2a), CD44v4/5
(clone 3D2, IgG1), CD44v5 (clone VFF-8, IgG1), CD44v6 (clone
VFF-18, IgG1), CD44v7 (clone VFF-9, IgG1), CD44v9 (clone
FW11-24-17, IgG1). Anti-Mer mAb (IgG1) was from R and D
systems. Control mouse immunoglobulins (IgG1 and IgG2a), rat
immunoglobulins (IgG2b), rabbit immunoglobulins, and F(ab9)2 goat
anti-mouse immunoglobulin FITC and HRP conjugates were from
DAKO (www.dako.com). The 5A4 and 8D2 mAb (IgG1, human
CD44) were generously provided by Dr. Graeme Dougherty
(University of Arizona, Tucson, AZ), 10.1 mAb (IgG1, human
CD64) was a gift of Prof. Nancy Hogg (Cancer Research UK,
London), IM7.8.1 mAb (rat IgG2b, murine CD44) [28] and F4/80
(rat IgG2b, mouse macrophage) were obtained from American Type
Culture Collection (www.lgcstandards.com). Hybridomas were
maintained in Dulbecco’s Modified Eagle’s Media containing 10%
Foetal calf serum and antibodies purified as described [24].
Human leukocyte Isolation and culture
Human peripheral blood was obtained from the antecubital vein
of healthy volunteers after obtaining informed written consent.
Ethics approval for granulocyte isolation was obtained from the
Lothian Research Ethics Committee; approval numbers #08/
S1103/38 or #1702/95/4/72, at the University of Edinburgh,
Queen’s Medical Research Institute, where participants were
recruited and experimentation was carried out. Blood was collected
into tubes containing sodium citrate (1% final concentration) to
prevent coagulation. Mononuclear (MNC) and polymorphonuclear
(PMN) leukocytes were isolated as described [29]. In brief,
erythrocytes were sedimented with 0.6% (w/v) dextran T500
followed by fractionation of leukocytes on a discontinuous
PercollTM gradient (prepared in Ca2+/Mg2+-free phosphate buff-
ered saline (PBS) with final concentrations of Percoll of 50, 63, and
73%) at 720 g for 20 min. MNC were aspirated from the 50/63
interface, and PMN from the 63/73% interface, and washed three
times in PBS (without Ca2+/Mg2+) before culture. PMN (resus-
pended at 46106 cells/ml in IDMEM containing 10% autologous
serum) were cultured at 37uC in a 5% CO2 atmosphere for 20 h in
Falcon tissue culture flasks (www.bdbiosciences.com). Cultured
PMN populations were .60% apoptotic as determined by
morphological analysis and annexin V binding, and ,5%
propidium iodide positive. MNC were plated at 46106 cells/ml in
IDMEM and incubated for 45–60 min, at 37uC, 5% CO2 after
which non adherent lymphocytes removed by washing with HBSS
(without Ca2+/Mg2+). Alternatively, monocytes were isolated by
negative selection using monocyte isolation kit II as specified by the
manufacturer (www.miltenyibiotech.com) and plated at 0.756106
cells/ml. Adherent monocytes were then cultured in vitro to generate
monocyte-derived macrophages for a period of 5–7 days in
IDMEM containing 10% autologous serum, with or without the
addition of 250 nM dexamethasone as detailed in the figure
legends.
Mice and induction of peritonitis
All mice, housed either in the University of Edinburgh or
National Kanker Instituut (Amsterdam) animal facilities were
humanely maintained and handled in accordance with the UK
Home Office Animals Scientific Procedures Act (Licence Number
60/3829). This licence was approved by the University of
Edinburgh Ethical Review Committee (approval ID PL08-08).
Mice were used between 8 and 12 weeks of age. C57BL/6J mice
were obtained from B&K (B&K, www.bku.com). CD44 2/2
animals backcrossed onto a C57BL/6J background were obtained
from Amgen (generously provided by Prof. Tak Mak). Lack of
CD44 expression in various cell populations was confirmed by PCR
and flow cytometry. Tiam-1 2/2 mice and strain matched FVB
mice were provided by Prof. John Collard and maintained at the
Nederlands Kanker Instituut in Amsterdam as described [30].
Sterile peritoneal inflammation was elicited by instillation of 2 ml of
4% Brewer’s thioglycollate as described [31]. Elicited cells were
harvested at days 1–5 by peritoneal lavage following sacrifice by
cervical dislocation, with 265 ml of sterile PBS. Cell recovery was
estimated by haemocytometer counts and the numbers of
macrophages, granulocytes and lymphocytes were estimated from
relative percentages of cells by microscopic examination of
cytocentrifuge preparations together with flow cytometric analysis
using laser scatter characteristics combined with mAb staining.
Isolation of bone marrow macrophages
Macrophages were prepared from the femurs of mice as
described [32]. Briefly the expanded ends of cleaned femurs were
removed with a scalpel and the bone marrow was extruded into a
sterile tube with 5 ml of DMEM containing antibiotics and 10%
FCS down the central cavity of the bone using a syringe with a
19G needle. A single cell suspension was obtained after repeated
aspiration and cells were resuspended at 16105 non-erythrocyte
Cross-Linking of Macrophage CD44
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cells/ml in complete DMEM containing 25% FCS and 25%
L929-conditioned media as a source of macrophage colony
stimulating factor. The media was replaced at 3 and 5 days and
bone-marrow derived macrophages were used between day 6–9
following isolation.
Macrophage phagocytosis assay
Monocyte-derived macrophages were cultured in 48 well tissue
culture plates as described above for assessment of phagocytosis of
apoptotic cells [33]. For experiments using inhibitors of phagocy-
tosis, monocyte-macrophages were washed once then incubated
with phagocytosis inhibitors (at the concentrations described in
figure legends) for 15 min prior to the phagocytosis assay. The
macrophage monolayer was then overlaid with apoptotic PMN
(washed and resuspended at a final concentration of 46106 cells/
ml in IDMEM) and incubated at 37uC, 5% CO2 for 30 min. Non
ingested PMN were removed by washing in IDMEM and
monolayers were then fixed in 2.5% glutaraldehyde. The
percentage of macrophages that were positive for staining for
myeloperoxidase activity with 0.1 mg/ml dimethoxybenzidine
and 0.03% (v/v) hydrogen peroxide was quantified microscopi-
cally by counting at least 500 cells in randomly selected fields per
well and an average between the duplicate wells calculated.
For flow cytometric determination of phagocytosis [34], PMN
were resuspended at 107 cells/ml in IMDM and incubated with
20 mM (final concentration) 5-chloromethylfluorescein diacetate
(CMFDA, Life Technologies; www.invitrogen.com) for 20 min
and then washed prior to culture for 20 h in IMDM containing
autologous serum as described above. Macrophage phagocytosis
was assessed by overlaying macrophage monolayers with apoptotic
PMN (washed and resuspended at a final concentration of 46106
cells/ml in IDMEM) and incubated at 37uC, 5% CO2 for 30 min.
Non-ingested PMN were carefully aspirated off and macrophages
detached by addition of trypsin/EDTA. The percentage of
macrophages that were fluorescent was then determined by flow
cytometric analysis.
For experiments to assess clearance of apoptotic cells in vivo,
CMFDA-labelled apoptotic human PMN were transferred into
the peritoneal cavity of mice [35]. Briefly, 100 mg of CD44 mAb
8D2 or 100 mg of IgG1 control (stock solution at 1 mg/ml in PBS)
was injected into the peritoneal cavity of either C57BL/6J wild-
type or CD44 2/2 mice. After 15 min, 1.56107 human PMN
that had been labelled with CMFDA as described above were
injected in 150 ml of PBS into the peritoneal cavity. After a further
7 min, the animals were sacrificed and the peritoneal cavity was
lavaged with 5 ml of PBS. Cell recovery was estimated by
haemocytometer counts and phagocytosis of PMN was estimated
by labelling macrophages with PE-conjugated F4/80 and
determining the proportion of dual fluorescent macrophages by
flow cytometry.
Flow cytometry
Flow cytometry for analysis of antibody binding was performed
essentially as described [29] with all incubations carried out on ice
to prevent internalisation of bound antibody. Macrophages were
detached from tissue culture plastic by incubation in PBS
containing 2 mM EDTA and 0.5% serum for 15–30 min. After
washing with ice-cold PBS containing 0.2% (w/v) bovine serum
albumin and 0.1% (w/v) sodium azide (PBN), cells (105/assay)
were pre-incubated for 10 min with 20% (v/v) normal rabbit
serum to block non specific binding of antibodies to Fcc receptors.
Cells were then incubated with saturating concentrations of mAb
for 30 min and washed twice in PBN prior to incubation with
FITC-conjugated F(ab9)2 goat anti-mouse immunoglobulin
(DAKO) for 30 min and washed twice more before analysis using
a FACScaliber flow cytometer (www.bdbiosciences.com) with
post-acquisition data analysis either using Cellquest (www.
bdbiosciences.com), Flowjo (www.flowjo.com) or Weasel (www.
wehi.edu.au) software.
Immunoprecipitation and western blotting
Adherent macrophage cultures were washed with PBS con-
taining0.1 mM NaVO3 plus protease inhibitor cocktail (www.
roche-applied-science.com), and were lysed by incubation with PBS
containing 1% NP-40, 0.1 mM NaVO3, and protease inhibitor
cocktail, 10 min on ice. Membrane and nuclear material were
removed by centrifugation at 14,000 g, 4uC, 30 min. Lysates were
‘‘pre-cleared’’ by incubation with protein-A agarose-coupled rabbit
anti-mouse IgG, 4uC, 30 min. The resulting lysates were tested for
protein concentration using a detergent compatible protein
estimation kit (www.piercenet.com) and equilibrated to contain
equivalent levels of protein. 100 ml of lysate (100–150 mg total
protein) was incubated with 1 mg of either mouse IgG control or
anti-paxillin mAb, 4uC, 30 min, shaking. Immunoprecipitation was
achieved by incubation for 30 min with protein-A coupled rabbit
anti-mouse IgG and washed twice in Tris buffered saline containing
0.1% Triton X-100, and once in 25 mM Tris plus 0.05% SDS.
Samples were resolved using a 9% reducing polyacrylamide gel and
transferred electrophoretically (50 V for 1 h) onto nitrocellulose
(GE Healthcare). For detection of phosphotyrosine, membranes
were blocked with TBS plus 0.05% Tween-20 (TBS-T) all other
blots with TBS-T plus 10% non-fat dried milk powder (w/v). Bound
antibodies were visualised with enhanced chemiluminescence as
described by the manufacturer (Pierce).
Assay for detection of activated Rac
Adherent macrophage cultures were lysed in RIPA buffer (Sigma)
containing protease inhibitor cocktail (Roche) plus 1 mM PMSF.
Lysates were cleared of membrane and nuclear material by
centrifugation, total protein estimated and levels equilibrated as
described for immunoprecipitation. 20 ml of lysate was removed for
estimation of total Rac protein and the remaining (approximately
300 mg) was incubated with GST-PAK (CRIB) fusion protein
coupled to Sepharose beads, 4uC, 1 h, with constant agitation [23].
Beads were washed 4 times in ice cold Tris buffer (50 mM Tris
pH7.2, 150 mM NaCl, 10 mM MgCl2, 1% Triton X-100, protease
inhibitor cocktail, 1 mM PMSF), and the amount of active Rac1
and Rac2 bound to PAK CRIB domain quantified by SDS PAGE
and western blotting as described for immunoprecipitation.
Statistics
Results are presented as mean 6 SEM and n = number of
independent experiments using cells obtained from different donors
or mice. Differences were analysed by ANOVA either using Mann-
Whitney test for comparison of two data sets or the Tukey multiple
comparison test using Instat software (www.graphpad.com).
Results and Discussion
Analysis of the mechanism of CD44 antibody-mediated
augmentation of phagocytosis
We previously reported that F(ab9)2 fragments of CD44 mAb
were able to augment macrophage phagocytosis of apoptotic cells
[24]. These data implicate a requirement for cross-linking of
CD44 for the augmentation of phagocytosis, whilst eliminating the
possibility that antibody-mediated bridging via FccR was involved.
To examine the requirement for antibody-induced redistribution
of cell surface CD44, we pre-treated macrophages with Fab9
Cross-Linking of Macrophage CD44
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fragments of a well characterised CD44 mAb (5A4) [24]. Fab9
fragments of 5A4 showed saturable binding to macrophages in
flow cytometry, demonstrating that binding was not compromised
by enzymatic digestion used during fragment preparation (data not
shown). In the absence of cross-linking, binding of 5A4 mAb Fab9
fragments failed to augment phagocytosis of apoptotic cells
(Fig. 1A). When bound 5A4 Fab9 fragments were cross-linked by
addition of F(ab9)2 anti-mouse immunoglobulins, we observed a
rapid increased in the proportion of macrophages capable of
phagocytosis of apoptotic PMN, unequivocally demonstrating a
requirement for cross-linking of CD44. These data provide
important evidence that augmentation of phagocytosis that we
observe does not involve antibody blockade of CD44 binding to
ligand or ‘‘masking’’ of CD44 epitopes that normally suppress
macrophage phagocytosis.
Comparison of phagocytosis by untreated and CD44-treated
macrophages in time course experiments indicated that CD44
cross-linking allows the recruitment of previously unresponsive
cells and does not simply act to improve the efficiency of
phagocytosis in responsive macrophages (Fig. 1B). Interestingly, in
these experiments there is an apparent difference in the duration
of the effects of CD44 mAb (compare Fig. 1A and 1B). One
possibility is that this reflects a difference in the extent of cross-
linking achieved using Fab9 and F(ab9)2 anti–mouse immunoglob-
ulin (Fig. 1A) when compared with intact antibody (Fig. 1B),
However, the rapid effect of cross-linking strongly suggests that
CD44 cross-linking initiates intracellular signal transduction events
that regulate macrophage phagocytic function.
We next examined the binding and functional effects of a large
panel of CD44 antibodies including mAb specific for isoforms
expressing different alternatively spliced exons. Expression of
CD44 variant isoforms was higher on monocyte-derived macro-
phages (Fig. 2A - black bars) than either glucocorticoid-treated
monocyte-derived macrophages (grey bars) or monocytes. In these
experiments, we included CD64 (FccRI) as a myeloid-specific
receptor, demonstrating similar patterns of expression to CD44v3,
CD44v5, and CD44v6, raising the possibility that this pattern of
expression simply reflected differentiation status. However,
expression of the haemopoeitic (unspliced) form of CD44 was
considerably higher on monocytes than either monocyte-derived
macrophage population [mean fluorescence for mono-
cytes = 20376147; monocyte-derived macrophages = 14716530;
and glucocorticoid-treated macrophages 8116355]. These data
would be consistent with induction of expression of variant
isoforms during monocyte differentiation and suppression of
variant isoform expression by glucocorticoids. Interestingly, all
CD44 mAb that bind the haematopoietic form that we have tested
potentiate phagocytosis of apoptotic neutrophils ([24] and data not
shown), whereas none of the isoform-specific CD44 antibodies had
any effect (Fig. 2B). One possibility is that a critical level of cross-
linking of membrane CD44 is required to confer a pro-phagocytic
signal that is not achieved following binding of the CD44 isoform-
specific antibodies. This suggestion would be consistent with data
from antibody titration studies which reveal a close correlation
between the level of binding of CD44 mAb to the macrophage
surface in flow cytometric analysis and augmentation of phago-
cytosis of apoptotic cells (data not shown). Alternatively, binding of
the variant CD44 mAb may not allow the correct juxtaposition of
CD44 in the membrane to confer signal transduction events.
Cell type specificity and role of opsonins in CD44
augmentation of phagocytosis
Our previously published work demonstrated a specific
augmentation of phagocytosis of apoptotic human PMN following
binding of CD44 mAb to huma monocyte/macrophages, with no
effect upon phagocytosis of apoptotic lymphocytes [24]. To further
investigate cell-type specificity of the augmentation of phagocytosis
following CD44 pre-treatment, we examined the effects of CD44
Figure 1. CD44 cross-linking promotes human macrophage phagocytosis of apoptotic human PMN. A) Monocyte-derived macrophages
were incubated with CD44 mAb 5A4 Fab9 fragments (squares) or control Fab9 (triangles) for 30 min prior to addition of F(ab9)2 goat anti-mouse
immunoglobulins (black symbols, solid line) or PBS control (gray symbols, dashed lines). Macrophages were then co-incubated with apoptotic targets
at 37uC for the times indicated prior to assessment of phagocytosis by microscopy. Results shown are mean6 SEM for n = 5 separate experiments. **
indicates significant difference between cross-linking versus non-cross-linked (p,0.01). B) Monocyte-derived macrophages were incubated with
CD44 mAb for 30 min to allow saturation of binding prior to addition of CMFDA-labelled apoptotic targets at 37uC for the times indicated.
Assessment of phagocytosis was made by flow cytometry (white bars = untreated; gray bars (CD44-treated). Data shown are mean percentage
phagocytosis 6 SEM for 3 independent experiments. At all time points examined except 5 min, CD44-treated cells exhibit significant augmentation
of phagocytosis (p,0.05).
doi:10.1371/journal.pone.0033142.g001
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mAb upon macrophage phagocytosis of apoptotic eosinophils, a
cell type that is closely related to the neutrophil in terms of
ontogeny and cell surface receptor profile. Although macrophage
phagocytosis of apoptotic PMN was augmented following pre-
treatment with CD44 mAb (24.666.1% phagocytosis for untreat-
ed v 45.5614.2% for CD44-treated), phagocytosis of apoptotic
eosinophils was not affected (40614% phagocytosis for untreated
v 38612.9% for CD44-treated, n = 3). We therefore conclude that
the augmentation of phagocytosis of apoptotic PMN is specific for
neutrophils.
We next examined the requirement for opsonins that are
present within serum for the CD44 antibody-mediated augmen-
tation of phagocytosis of apoptotic neutrophils. Experiments using
neutrophils that had undergone apoptosis in the presence of
human serum albumin alone or in the presence of either heat-
inactivated or untreated human serum revealed that CD44 was
able to induce macrophage phagocytosis in the absence of
opsonins that might be present in serum, including complement
components and the phosphatidylserine binding protein S
(Fig. 3A). In the presence of serum albumin alone, phagocytosis
was increased approximately 1.5-fold from 27.269% to
40.169%. In the presence of autologous serum, CD44 augmented
recognition by a similar percentage, from 28.868% to 47.8616%,
an effect that was maintained when neutrophils were cultured in
the presence of heat-inactivated serum (data not shown).
The lack of requirement for a serum factor in the augmentation
of phagocytosis by CD44 mAb indicates that the mechanism of
action is distinct from the augmentation observed following
treatment of monocyte-macrophages with glucocorticoids. We
therefore investigated whether there were synergistic effects of
CD44 cross-linking upon augmentation of phagocytosis of apoptotic
cells following treatment with glucocorticoids. Interestingly, these
experiments revealed that there was no effect of CD44 mAb upon
phagocytosis of apoptotic neutrophils by glucocorticoid-treated
macrophages, either in the presence or absence of protein S
(Fig. 3B), despite high levels of cell surface expression of CD44 on
these cells ([21] and data not shown). Together, these data indicate
that CD44 promotes an opsonin-independent pathway for
phagocytosis of apoptotic neutrophils that does not involve the
Mer/Protein S-dependent mechanism utilised by glucocorticoid-
treated macrophages [36].
CD44-mediated regulation of macrophage cytoskeleton
In view of previous reports demonstrating antibody-induced
shedding of CD44 from the plasma membrane [37], we examined
whether macrophages treated with CD44 mAb exhibited down-
regulation of CD44 expression. However, in a series of ex-
periments where macrophages were pre-treated with CD44 mAb
and then cultured at 37uC for up to 3 h, we did not observe
reduction in the levels of CD44 expressed at the cell surface by
flow cytometry (data not shown). In microscopy analysis, the
appearance of macrophages treated with CD44 mAb was
suggestive of altered adhesion status. We therefore investigated
macrophage capacity for migration following treatment with
CD44 mAb using a ‘‘scratch’’ assay in which monolayers of
macrophages were disrupted with a pipette tip [38] and the
migration of cells monitored using time lapse video microscopy
over an 8 hour period. In these assays, the rate of macrophage
migration into the wound was significantly attenuated following
pre-incubation with CD44 mAb, reducing the rate of macrophage
migration by approximately 30% (Fig. 4A and B).
Examination of actin localisation in CD44-treated macrophages
using immunofluorescence microscopy revealed rapid alteration of
cytoskeletal organisation independently of the presence of apoptotic
targets. In the representative micrographs shown in Fig. 4C and D,
marked changes in the organisation of podosome-rich regions were
apparent following CD44 antibody treatment. Quantification of the
numbers of macrophages displaying altered cytoskeletal organisa-
Figure 2. CD44 variant antibodies do not promote phagocytosis of apoptotic PMN. A) Monocytes (white bars) or monocyte-derived
macrophages cultured for 5 days in the absence (black bars) or presence of dexamethasone (gray bars) were incubated with different isoform-specific
CD44 mAb or CD64 mAb (10.1) for 30 min to allow saturation of binding prior to addition of FITC-conjugated F(ab9)2 goat anti-mouse
immunoglobulins and assessment of binding by flow cytometry. Data shown are the average mean fluorescence intensity 6 SEM for 4 independent
experiments. B) Monocyte-derived macrophages were incubated with isoform-specific CD44 mAb for 30 min to allow saturation of binding prior to
addition CMFDA-labelled apoptotic targets at 37uC for the times indicated. Assessment of phagocytosis was made by flow cytometry. Data shown are
mean percent phagocytosis 6 SEM from 4 different macrophage preparations, no significant augmentation of phagocytosis compared with control
was observed with any of the variant antibodies examined (NS).
doi:10.1371/journal.pone.0033142.g002
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tion (29.564% untreated macrophages compared with 54.164%
CD44-treated macrophages showing the presence of multiple
patches of podosome-rich regions, n = 3) suggested a role for
CD44 cross-linking in the control of cytoskeletal dynamics.
CD44-mediated macrophage signal transduction events
In terms of specificity of CD44 effects, a number of molecules
that might mediate rapid signalling events have been proposed to
interact with CD44, particularly with respect to cytoskeletal
organisation, including src family kinases (e.g. p56lck) [39] and
members of the ezrin/radixin/moesin family [40]. Although we
have previously shown that elevation of cAMP within macro-
phages acts to inhibit phagocytosis, cross-linking of CD44 might
lead to altered phagocytosis via redistribution or local alteration of
intracellular cAMP levels mediated by CD44 interactions with
ezrin, a protein which can serve to anchor protein kinase A [41].
Although the overall levels of phagocytosis were different in
untreated and CD44-treated cells, dibutyryl cAMP displayed
similar inhibitory effects on phagocytosis (Fig. 5A) with a
concentration response that paralleled that previously seen for
untreated macrophage phagocytosis of apoptotic neutrophils [41].
We further tested whether inhibition of protein kinase A would be
influenced by H-89, a broad-specificity inhibitor of protein kinase
A. In these experiments, pretreatment of macrophages with
10 mM H-89 did not affect CD44-mediated augmentation of
phagocytosis (Control = 22.662.8; H-89 20.264.2; CD44-treat-
ed = 40.762.9; H-89+CD44-treated = 41.963.9, n = 4). Our in-
terpretation is that CD44 does not act to augment phagocytosis
through effects upon protein kinase A activity.
Since intracellular calcium has a key role in cytoskeletal
regulation, we next investigated the impact of binding of CD44
antibodies upon mobilisation of intracellular calcium stores in
macrophages. In experiments in which Fura-2 loaded macrophages
were treated with CD44 antibodies we did not observe any
alteration in baseline levels of intracellular calcium (data not shown),
suggesting that calcium release is not required for the effects of
CD44 upon either cytoskeletal alteration or functional effects upon
phagocytosis or migration. Interestingly, although PI-3K activity
has been suggested to be critical for phagocytosis of apoptotic cells
[42], we found that blockade of PI3-K with LY 294002 did not
affect phagocytic uptake of apoptotic cells by CD44-treated
macrophages, despite fully blocking phosphorylation of Akt
(Fig. 5B and data not shown).
We next used a series of inhibitors of key signalling pathways in
macrophages, including the broad spectrum tyrosine kinase
inhibitor (genistein), the src kinase inhibitor (PP2) and an inhibitor
of MEK (PD98059). Surprisingly, we did not observe inhibition of
CD44-augmented phagocytosis with any of these inhibitors
(Fig. 5C–E), despite their key role in adhesion regulation.
However, immunoblot analysis of lysates prepared from CD44-
treated macrophages in the absence of apoptotic targets
demonstrated that paxillin phosphorylation was increased in a
time-dependent manner following CD44 cross-linking (Fig. 6A),
consistent with the changes in actin/paxillin-rich podosome
structures we observed in CD44-treated macrophages. Although
these data implicate tyrosine phosphorylation as an important
event in the regulation of macrophage adhesion by CD44, the
inhibitor data presented here suggests that tyrosine phosphoryla-
tion is not required for the observed augmentation of phagocytosis
of apoptotic neutrophils.
The activity of Rho family GTPases (including, Rac and cdc42)
has been closely linked to control of apoptotic cell phagocytosis
[43]. We utilized ‘‘pull-down’’ assays with the CRIB domain of
p21activated kinase to assess the effects of CD44 upon Rac
activation. In untreated cells, there was a low basal level of both
Rac1 and Rac2 activity. However, following CD44 antibody
treatment, we found a rapid and specific induction of Rac2
Figure 3. CD44 promotes a serum-opsonin independent mechanism of phagocytosis of apoptotic neutrophils. A) Monocyte-derived
macrophages were incubated in the absence or presence of CD44 mAb for 30 min prior to addition CMFDA-labelled neutrophils that had been
cultured either in human serum albumin (Albumin) or autologous serum (Serum). Assessment of phagocytosis was made by flow cytometry, data are
mean 6 SEM from 5 independent experiments. Although CD44 augmented phagocytosis relative to untreated cells (* = p,0.05), no significant
differences between phagocytosis of PMN cultured in albumin versus serum was found following CD44 treatment. B) Glucocorticoid-treated
monocyte-derived macrophages were incubated in the absence or presence of CD44 mAb for 30 min prior to addition CMFDA-labelled neutrophils
that had been cultured in human serum albumin. Phagocytosis was assessed in the presence of 100 ng/ml of protein S for 30 min and the proportion
of phagocytic macrophages determined by flow cytometry. Data shown are mean percentage phagocytosis6 SEM from 5 independent experiments.
Although the presence of protein S augmented phagocytosis by glucocorticoid-treated macrophages (* = p,0.05), there was no significant
difference between phagocytosis of PMN in the presence or absence of protein S following CD44 treatment.
doi:10.1371/journal.pone.0033142.g003
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activation but no effect on Rac1 (Fig. 6B and data not shown). The
specificity for CD44 induction of Rac2 activity may explain our
observations that CD44 does not augment phagocytosis by non-
professional phagocytes such as fibroblasts which do not express
Rac2.
The effects of CD44 mAb on phagocytosis in Tiam-1- and
CD44-deficient mice
In view of the CD44-induced Rac activation and previous reports
of association of CD44 with Tiam-1 [44], we next examined whether
macrophages derived from Tiam-1 2/2 mice were able to exhibit
augmentation of phagocytosis of apoptotic cells following CD44
mAb treatment. Experiments using either peritoneal or bone-
marrow-derived macrophages from C57BL/6J wild-type and CD44
2/2 mice demonstrated that anti-mouse CD44 mAb IM7 failed
to augment phagocytosis of apoptotic human neutrophils in the
absence of CD44 expression (wild-type macrophages: 26.9612.3%;
CD44-treated wild-type macrophages: 39.4615.2%; CD442/2:
27.168.8%; CD44-treated CD442/2: 29.5610.8%; n = 6). As
shown in Fig. 7A and B, phagocytosis of apoptotic human
neutrophils by mouse peritoneal macrophages was augmented
following pre-treatment with rat anti-mouse CD44 mAb IM7.8.1.
Macrophages from Tiam-1 2/2 mice also exhibited increased
phagocytosis of apoptotic neutrophils following treatment with
CD44 mAb suggesting that Tiam-1 is not required to confer
augmented phagocytosis (Fig. 7A and B).
We next used a model of inflammation in which apoptotic
human neutrophils were injected into the peritoneal cavity of
mice. We pre-injected either a CD44 mAb which cross-reacts with
mouse CD44 (clone 8D2) or an IgG1 control into the peritoneal
cavity prior to adoptive transfer of neutrophils. The proportion of
macrophages which phagocytosed apoptotic neutrophils was then
estimated by flow cytometry as described [35]. Consistent with
published data [35], results from preliminary experiments
indicated that clearance of apoptotic cells occurred extremely
rapidly and we therefore used an time point of 7 minutes to
Figure 4. Effect of CD44 on macrophage migration. A) Monocyte-derived macrophages were incubated in the absence or presence of CD44
mAb for 30 min to binding prior to ‘‘wounding’’ of the cell monolayer. Assessment of migration into the wounded area was made by microscopy at
18 h, data shown are mean number of cells present in the wound 6 SEM from 6 separate experiments. In paired analysis there is a significant
reduction of migration in the presence of CD44 mAb (p,0.05). B) Monocyte-derived macrophages were incubated in the absence or presence of
CD44 mAb for 30 min to binding prior to ‘‘wounding’’ of the cell monolayer. Assessment of macrophage migration into the wounded area was made
by quantification of the numbers of macrophages in the wound using time lapse microscopy images captured over 10 hours. Measurements for
untreated macrophages are indicated by gray diamond symbols and CD44-treated macrophages by black squares. Data are mean number of cells
observed in the wound 6 SEM from 3 independent experiments. * indicates that migration was significantly reduced by CD44 mAb from 3 h
onwards (p,0.05). Monocyte-derived macrophages adherent to glass coverslips were treated with media (C) or CD44 mAb (D) for 30 min prior to
fixation with paraformaldehyde and staining for filamentous actin with rhodamine phalloidin. Representative micrographs show localisation of
podosome-like structures in adherent macrophages (C) and marked redistribution that is observed following CD44 antibody binding (D). Scale
bar = 10 mm.
doi:10.1371/journal.pone.0033142.g004
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examine the earliest stages of apoptotic cell clearance when we
would predict CD44 cross-linking to have the greatest impact. In
these experiments, CD44 mAb pre-treatment resulted in augmen-
tation of phagocytosis (Fig. 8A and B), suggesting that CD44 cross-
linking was capable of augmentation of apoptotic cell phagocytosis
in vivo. Importantly, in experiments using CD44 2/2 mice, pre-
injection of CD44 mAb had no significant effect on macrophage
phagocytosis, ruling out the possibility that opsonisation of
apoptotic targets accounted for the observed effects (Fig. 8B).
We did not examine whether there was augmentation of
phagocytosis of apoptotic neutrophils from CD44 2/2 by wild
type macrophages. Thus, we cannot exclude the interesting
possibility that CD44 mAb are able to potentiate phagocytosis
by bridging apoptotic neutrophils, but not apoptotic eosinophils or
apoptotic lymphocytes to the macrophage surface.
Previously published studies reported that CD44 deficiency
exacerbates inflammation in the lung, increasing neutrophil
recruitment and compromising resolution of inflammation
[45,46]. Similarly, lack of CD44 increased macrophage numbers
within atherosclerotic lesions in ApoE deficient animals [47]
suggesting that CD44 acts as a critical regulator of inflammatory
cell migration in vivo. However, inflammatory cell recruitment in
the peritoneal cavity is not affected by lack of CD44 as
inflammatory cell numbers in response to LPS or E. coli infection
in the peritoneal cavity is similar in wild-type and CD44 2/2
mice [48]. Since our data using adoptive transfer of apoptotic
human neutrophils suggests that CD44 ligation can augment
phagocytic clearance, we sought to examine whether lack of CD44
expression would influence progression and resolution of inflam-
mation in the peritoneal cavity. Our in vitro data would predict that
Figure 5. Effects of pharmacological inhibition of signalling pathways in macrophages upon CD44-augmentation of phagocytosis.
A) Monocyte-derived macrophages were incubated with CD44 mAb for 30 min prior to addition of dibutyryl cAMP at concentrations shown.
Macrophages were then co-incubated with apoptotic targets at 37uC for 30 min prior to assessment of phagocytosis by microscopy. Results shown
are mean percentage phagocytosis for 3 independent experiments. B) Monocyte-derived macrophages were pre-incubated with 10 mM LY294002 at
37uC and then co-incubated with CD44 mAb for 30 min prior to addition of CMFDA-labelled apoptotic targets. After 30 min, assessment of
phagocytosis was made by flow cytometry. Results shown are mean percentage phagocytosis 6 SEM for 5 independent experiments. C)Monocyte-
derived macrophages were pre-incubated with 50 nM PD98059 at 37uC and then co-incubated with CD44 mAb for 30 min prior to addition of
CMFDA-labelled apoptotic targets. After 30 min, assessment of phagocytosis was made by flow cytometry. Results shown are mean percentage
phagocytosis 6 SEM for 3 independent experiments. D) Monocyte-derived macrophages were pre-incubated with 25 mM PP2 at 37uC and then co-
incubated with CD44 mAb for 30 min prior to addition of CMFDA-labelled apoptotic targets. After 30 min, assessment of phagocytosis was made by
flow cytometry. Results shown are mean percentage phagocytosis 6 SEM for 4 independent experiments. E) Monocyte-derived macrophages were
pre-incubated with 25 mM Genistein at 37uC and then co-incubated with CD44 mAb for 30 min prior to addition of CMFDA-labelled apoptotic
targets. After 30 min, assessment of phagocytosis was made by flow cytometry. Results shown are mean percentage phagocytosis 6 SEM for 3
independent experiments. In panels B-E there was no statistical difference between the percentage phagocytosis recorded in the presence or
absence of pharmacological inhibitor following CD44 mAb treatment.
doi:10.1371/journal.pone.0033142.g005
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lack of CD44 expression may delay clearance of apoptotic
neutrophils and possibly promote emigration of macrophages
from inflammatory sites. In the absence of CD44 expression,
neutrophil clearance might be delayed and macrophage emigra-
tion from the peritoneal cavity might be enhanced.
We therefore undertook a temporal analysis (days 1–4) of the
cellular infiltrates in experimental thioglycollate-induced peritoni-
tis in wild-type and CD44-deficient animals. There was no
difference in the cellular composition of lavage obtained from
wild-type or CD44-deficient animals in the absence of any
treatment (Fig. 9). Following thioglycollate-induced sterile perito-
nitis, we observed increased numbers of neutrophils in the
peritoneal cavity of both wild-type and CD442/2 animals after
24 h. By day 2, neutrophil numbers in the peritoneal lavage were
lower in both wild-type and CD442/2 animals, with increased
numbers of cells with monocyte/macrophage morphology, consis-
tent with the pattern of cell recruitment we have seen previously
following thioglycollate treatment [31]. There was a trend for higher
numbers of eosinophils in the lavage of CD44 2/2 animals,
although this did not reach statistical significance.
Although data presented here suggest that lack of CD44
expression does not affect cell recruitment or clearance, it remains
possible that CD44 may be differentially involved in the regulation
of inflammatory cell numbers in different anatomic compartments.
Consistent with this suggestion, CD44 may play an important role
in the recruitment of macrophages to atherosclerotic lesions,
possibly by promoting expression of VCAM-1 [47]. Furthermore,
although CD442/2 lymphocytes were found to traffic normally
following transfer into naı¨ve wild-type animals, clear differences
were observed in trafficking of CD442/2 cells in arthritic
recipients [49]. These studies raise the possibility that the influence
of CD44 on cellular recruitment, clearance and emigration
patterns may depend on both the tissue type and the inflammatory
stimulus. In addition there may be compensatory mechanisms
involved that compensate for the lack of CD44 expression in
different tissues/organs.
Figure 6. CD44-augmentation of phagocytosis is associated
with phosphorylation of paxillin and Rac2 activation. A)
Monocyte-derived macrophages were incubated with CD44 mAb at
37uC for different time points up to 60 min prior to lysis in RIPA buffer.
Immunoblot analysis of tyrosine phosphorylation of paxillin revealed a
time-dependent increase in phosphorylation following CD44 antibody
binding. Image shows representative autoradiograph of a single
experiment from 3 that were performed. Densitometric analysis of
the phosphopaxillin using ImageJ (http://rsbweb.nih.gov/ij/) confirms
increased phosphorylation of paxillin following CD44 treatment. For
control phosphopaxillin levels at 0, 15, 30, 45 and 60 min was 7.7, 9.9,
9.3 and 8.2 respectively. In contrast, phosphopaxillin levels following
CD44 cross-linking were 3.7, 8.8, 13.7, 12.4 and 15.6 at 0, 15, 30, 45 and
60 min respectively. Molecular weight standards shown in KDa. B)
Monocyte-derived macrophages were incubated with either control
IgG1 or CD44 mAb at 37uC for different times up to 20 min prior to lysis
in RIPA buffer as indicated. Pull down assays using PAK CRIB agarose
beads revealed a robust increase in GTP-bound Rac2 in the presence
but not absence of CD44 antibody binding. A representative
autoradiograph from a single experiment (from 5 that were performed)
is shown.
doi:10.1371/journal.pone.0033142.g006
Figure 7. Augmentation of phagocytosis by CD44 in Tiam-12/2
mice. A) Peritoneal macrophages from wild-type (FVB) and Tiam-12/2
mice were pre-treated with CD44 mAb IM7.8.1 or rat IgG2b control prior
to incubation with apoptotic human PMN. After 30 min phagocytosis
of apoptotic PMN was determined by microscopy. Results show
mean percentage phagocytosis 6 SEM for macrophages derived from
4 separate animals. B) Representative microscopy images showing
Tiam12/2 peritoneal macrophages that have been pre-treated with or
without CD44 mAb IM7.8.1 prior to incubation with apoptotic human
PMN and then stained for myeloperoxidase activity. Scale bar = 20 mm.
doi:10.1371/journal.pone.0033142.g007
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Conclusions
We present evidence that definitively demonstrates cross-linking of
macrophage CD44 rapidly and specifically augments macrophage
phagocytosis of apoptotic neutrophils. Promotion of the phagocytic
phenotype following CD44 cross-linking induces rapid re-organisation
of paxillin and actin containing ‘‘podosome-like’’ adhesions, altered
phosphorylation of paxillin and activation of Rac2. These cytoskeletal
rearrangements are associated with reduced macrophage migration
following CD44 cross-linking and we speculate that CD44 cross-linking
favours the stabilisation of interaction of macrophages with apoptotic
neutrophil targets that promotes their subsequent internalisation.
Figure 8. Effects of CD44 cross-linking on phagocytosis of human apoptotic PMN transfered into the peritoneal cavity of mice. A)
CMFDA-labelled human apoptotic neutrophils were transferred into the peritoneal cavity of mice that had been previously injected with CD44 mAb,
8D2 or mouse IgG1 control antibody. Phagocytosis of apoptotic cells was determined by flow cytometry following labelling of mouse macrophages
with PE-conjugated F4/80. Representative histograms show Forward Scatter versus FL-1 for IgG1 treated versus 8D2 treated animals – representative
of 4 independent experiments that were performed. B) Wild-type (C57BL/6J) or CD442/2 mice were pre-injected with either IgG1 (white bars) or
CD44 mAb (8D2 – black bars) into the peritoneal cavity prior to injection of human apoptotic neutrophils. Quantification of phagocytosis by
peritoneal macrophages lavaged from either wild type (C57BL/6J) or CD44 2/2 was made by flow cytometry as described for (A) above. For C57BL/
6J (A) results shown are the mean 6 SEM for 10 separate animals. For C57BL/6J (B) and CD44 2/2, results are from 4 independent experiments. **
indicates results are statistically significant (p,0.01).
doi:10.1371/journal.pone.0033142.g008
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